Dyadic highlights accelerated C1 platform interest amid Ebola preparedness and commercial adoption

DYADIC INTERNATIONAL INC

C1 platform can produce purified antigen or monoclonal antibody in ~15 days, says company.
Collaborations: Scripps Research (Ebola, hantaviruses); CEPI Ebola funding proposals; Fondazione Biotecnopolo di Siena (Ebola, hantavirus antibodies).
Commercial milestones: recombinant human albumin via Proliant Health; recombinant DNase I via Fermbox Bio; bovine chymosin via Inzymes.
Estimated addressable market >$25B across life sciences, food/nutrition, bioindustrial applications.
DYAI-100 clinical study showed C1-produced antigens were generally safe and well tolerated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.